Drs. Julie Magarian Blander and Steven Lipkin are award recipients of the 2018 Daedalus Fund for Innovation. This award is given to advance early-stage reserach projects that have significant commercial potential for translation of their discoveries into new and more effective treatments for patients. To read more, click here. Donor gift establishes Friedman Center for Nutrition and Inflammation, an innovative cross-campus center dedicated to improving human health through research in the complex relationship between nutrition, inflammation and the development of disease. To read more, click here. The Jill Roberts Institute has been busy with two studies published this month! From the Iliev Lab, the study "Sensing of Fungi by Gut Immune Cells Can Contribute to Airway Allergic Diseases," was published online on November 29 in Cell Host and MicrobeTo read more, click here. From the Longman Lab, the study, "Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis," was published on December 11 in Immunity. To read more, click here.  The Kenneth Rainin Foundation awarded Dr. Iliyan Iliev and colleagues from Mount Sinai a $250,000 Synergy Award to examine the composition of the fungal community in babies born to mothers with inflammatory bowel disease. To read more, click here. Dr. Randy Longman received the Irma T. Hirschl Career Scientist Award and the New York Crohn’s Foundation Award.    

The Jill Roberts Institute for Research in Inflammatory Bowel Disease

You are here

Randy Longman, M.D., Ph.D.

Assistant Professor of Medicine

I am a gastroenterologist and mucosal immunologist focused on basic research to understand the causes and to develop new therapies for inflammatory bowel diseases (IBD).  Inflammatory bowel disease (IBD) affects over 2 million Americans.  While pharmacologic advances have improved the care of these patients, many still have refractory disease with significant morbidity.  IBD includes two distinct clinical phenotypes called Crohn’s disease and ulcerative colitis.  Genetic polymorphisms correlate with disease susceptibility, but they are rarely fully penetrant reflecting a central role for environmental triggers in disease pathogenesis.  While indeed certain luminal microbes may act as opportunistic pathogens causing infection and inflammation, we and others have shown that microbiota function as a double-edged sword to simultaneously suppress aberrant immune cell activation (homeostatic inhibition) and maintain homeostasis (homeostatic induction) at mucosal surfaces.  Thus, the major focus of our work is to define cellular and molecular regulation of innate intestinal barrier immunity and to harness the power of IBD-associated microbiota to develop novel diagnostic and therapeutic approaches to medically refractory IBD.

Education and Training

  • M.D., Weill Cornell Medical College 2007
  • Ph.D., The Rockefeller University 2006

 

View Recent Publications

 

Grants awarded

Weill Cornell Medicine The Jill Roberts Institute for Research in Inflammatory Bowel Disease 413 E 69th Street, 7th Floor New York, NY 10021 Phone: (646) 962-6312